Want to see IN:TAKE full AI Analyst Report?
Top Page
TAKE Solutions Limited
(TAKE)
Select Model
Select Model
Rating:45Neutral
Price Target:
₹10.00
▼(-51.83% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak/volatile financial performance—negative core profitability and two consecutive years of negative operating cash flow despite positive net income—along with bearish technicals (price below all key moving averages and negative MACD). Valuation is only a mild positive with a mid-range P/E and no dividend yield data to offset the operating and trend risks.
Positive Factors
Debt Reduction
Zero reported debt in FY2025 and FY2026 materially lowers interest and refinancing exposure, giving the company more financial flexibility than in earlier leveraged periods. This provides a useful buffer while management works through volatile earnings and cash generation.
Negative Factors
Weak Core Profitability
Negative gross and operating profit indicate that reported FY2026 earnings were not supported by healthy core operations. Dependence on below-the-line items makes profitability less sustainable, limits internal funding capacity, and increases the risk that earnings will remain inconsistent.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Zero reported debt in FY2025 and FY2026 materially lowers interest and refinancing exposure, giving the company more financial flexibility than in earlier leveraged periods. This provides a useful buffer while management works through volatile earnings and cash generation.
Read all positive factors
TAKE Solutions Limited (TAKE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.53B
Dividend Yield1.03%
Average Volume (3M)81.23K
Price to Earnings (P/E)11.7
Beta (1Y)1.40
Revenue GrowthN/A
EPS Growth-68.34%
CountryIN
Employees5
SectorGeneral
Sector StrengthN/A
IndustryInformation Technology Services
Share Statistics
EPS (TTM)0.87
Shares Outstanding147,934,000
10 Day Avg. Volume63,335
30 Day Avg. Volume81,228
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.8
Revenue Forecast (FY)₹15.22B
TAKE Solutions Limited Business Overview & Revenue Model
Company Description
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, th...
How the Company Makes Money
TAKE primarily makes money by selling technology and services to clients in regulated life-sciences markets. Key revenue streams typically include (1) services revenue from IT consulting, implementation, customization, validation, and ongoing mana...
TAKE Solutions Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 845.59M | 541.85M | 0.00 | 656.08M | 1.89B | 6.53B |
| Gross Profit | -36.00K | -4.44M | -450.00K | 411.67M | 1.06B | 4.60B |
| EBITDA | -19.02M | -19.14M | 27.44M | -1.05B | -209.79M | 269.00M |
| Net Income | 128.22M | 108.49M | 374.67M | -1.20B | -1.00B | -7.82B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 362.41M | 364.79M | 881.05M | 2.24B | 12.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.80M | 184.41M | 156.91M | 8.49M | 113.36M | 290.71M |
| Total Debt | 0.00 | 0.00 | 0.00 | 370.85M | 463.69M | 779.90M |
| Total Liabilities | -310.01M | 52.40M | 159.52M | 969.78M | 1.16B | 10.42B |
| Stockholders Equity | 310.01M | 310.01M | 205.27M | -88.73M | 1.09B | 1.81B |
Cash Flow | ||||||
| Free Cash Flow | -31.39M | 0.00 | -163.66M | 14.00M | -123.81M | 890.99M |
| Operating Cash Flow | -31.39M | -27.76M | -163.66M | 93.16M | 200.15M | 1.20B |
| Investing Cash Flow | 270.00K | 1.00K | 220.20M | -74.62M | -21.25M | -306.41M |
| Financing Cash Flow | -130.00K | -3.75M | -32.39M | -117.35M | -357.21M | -545.17M |
TAKE Solutions Limited Technical Analysis
Negative
20.76
Price Trends
15.44
Negative
20.06
Negative
30.02
Negative
Market Momentum
-1.37
Positive
30.01
Neutral
5.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TAKE, the sentiment is Negative. The current price of 20.76 is above the 20-day moving average (MA) of 12.22, above the 50-day MA of 15.44, and below the 200-day MA of 30.02, indicating a bearish trend. The MACD of -1.37 indicates Positive momentum. The RSI at 30.01 is Neutral, neither overbought nor oversold. The STOCH value of 5.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TAKE.
TAKE Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹144.20B | 52.41 | ― | 0.55% | -6.72% | -22.67% | |
56 Neutral | ₹23.15B | 33.95 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹147.74B | 66.58 | ― | 0.34% | -3.41% | -56.45% | |
49 Neutral | ₹543.47B | 97.78 | ― | 0.15% | 9.83% | 5.07% | |
45 Neutral | ₹1.53B | 11.69 | ― | 1.03% | ― | -68.34% | |
43 Neutral | ₹182.47B | -374.95 | ― | ― | 27.15% | 40.46% |
* General Sector Average
IN:TAKE
TAKE Solutions Limited
10.34
-12.16
-54.04%
IN:BIOCON
Biocon Limited
333.80
-31.66
-8.66%
IN:CONCORDBIO
Concord Biotech Ltd.
1,378.35
-45.72
-3.21%
IN:DCAL
Dishman Carbogen Amcis Ltd.
147.65
-147.15
-49.92%
IN:SYNGENE
Syngene International Ltd.
366.00
-289.29
-44.15%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,591.25
-223.60
-12.32%
TAKE Solutions Limited Corporate Events
TAKE Limited Appoints New Internal Auditor for FY 2025-26
Sep 1, 2026
TAKE Limited’s board has approved the appointment of M/s. Tejas Nadkarni Associates, a Mumbai-based firm of chartered accountants, as the company’s internal auditor for the financial year 2025-26, effective September 1, 2026. The one-...
TAKE Limited Shareholders Approve Appointment of New Managing Director via Postal Ballot
Aug 17, 2026
TAKE Limited has announced the results of a postal ballot process conducted via remote e-voting and physical ballot forms, undertaken pursuant to Indian listing regulations. The company reported that the resolution to appoint Mr. Sunil Patra as Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.